InOrpha

InOrpha is a French biotechnology company dedicated to developing innovative treatments for rare orphan diseases, with a primary focus on nephropathic cystinosis. The company's lead program involves a pharmacological chaperone approach designed to restore the function of the defective cystine transporter protein. By targeting the underlying genetic cause of the disease rather than just managing symptoms, InOrpha aims to provide a more effective therapeutic option for patients suffering from this lysosomal storage disorder. The company operates out of the Paris region and leverages expertise in molecular biology and rare disease drug development.